The state-of-the-art facility enhances support for complex modalities across all phases of drug development

Key facts

• Thermo Fisher opens new bioanalytical and biomarker laboratory in Gothenburg, Sweden
• Designed to deliver comprehensive, full-service bioanalytical and biomarker solutions
• Supports pharmaceutical and biotechnology customers across all phases of drug development
• Helps customers globally accelerate innovation and bring new therapies to patients faster

Thermo Fisher Scientific, the world leader in serving science,  announced the opening of a new bioanalytical and biomarker laboratory in Gothenburg, Sweden, located within GoCo Health Innovation City. This new facility expands the company’s global bioanalytical capabilities to support pharmaceutical and biotechnology customers across all phases of drug development.

With state-of-the-art instrumentation and Good Laboratory Practice (GLP) capabilities, the laboratory provides rapid, reliable bioanalytical and biomarker services across the full drug development lifecycle, from preclinical studies through post-approval. Its advanced technology suite includes cell-based assays, immunochemistry, liquid chromatography-mass spectrometry, molecular genomics, flow cytometry and proteomics, supporting both small molecules and complex therapeutic modalities such as peptides, antibodies, oligonucleotides, and cell and gene therapies.

“Our new Gothenburg laboratory is purpose-built to address the evolving needs of modern drug development, particularly as therapies become more complex and data requirements increase,” said Leon Wyszkowski, president, analytical services, clinical research, Thermo Fisher Scientific. “By investing in advanced capabilities and strategic locations, such as Gothenburg, we are helping our customers in Europe and globally accelerate innovation and bring new therapies to patients faster.”

Thermo Fisher Scientific's PPD™ Laboratory services support clinical trials at all levels and offers integrated support through its network of bioanalytical, biomarker, GMP, vaccine sciences and central labs to enhance clinical trial and drug development efficiency. The new lab in Gothenburg complements the business’ other bioanalytical labs in Richmond, Virginia, and Suzhou, China, and it reinforces the company’s long-term commitment to the Swedish life sciences ecosystem and continued growth as a major employer and investor in the region.